检索结果-南通市图书馆

The multispeciality approach to the management of localised kidney cancer

四川生理科学杂志 2022年第7期44卷 1169-1169页

作者： Grant D Stewart Department of Surgery University of Cambridge Cambridge Biomedical Campus Cambridge UK CRUK Cambridge Centre University of Cambridge Cambridge Biomedical Campus Cambridge UK Department of Urology Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust Cambridge UK Department of Urology Charité - Universitätsmedizin Berlin Berlin Germany Division of Nephrology and Dialysis ASST Fatebenefratelli Sacco Fatebenefratelli Hospital Milan Italy Specialist Centre for Kidney Cancer Royal Free Hospital London UK Division of Surgery and Interventional Science University College London London UK The Netherlands Cancer Institute Amsterdam Netherlands School of Allied Health Anglia Ruskin University Cambridge UK Department of Pathology and Molecular Pathology University Hospital Zurich Zurich Switzerland Department of Radiology University of Cambridge Cambridge Biomedical Campus Cambridge UK Sir Peter MacCallum Department of Oncology University of Melbourne Peter MacCallum Cancer Centre Melbourne VIC Australia Department of Biomedical Sciences and Human Oncology University of Bari Aldo Moro Bari Italy Division of Medical Oncology AOU Consorziale Policlinico di Bari Bari Italy Department of Clinical and Biomedical Sciences Università di Milano Milan Italy

Historically,kidney cancer was approached in a siloed single-speciality way,with urological surgeons managing the localised stages of the disease and medical oncologists caring for patients if metastases ***,improvements in the management of localised kidney cancer have occurred rapidly over the past two decades with greater understanding of the disease biology,diagnostic options,and innovations in curative *** developments are favourable for patients but provide a substantially more complex landscape for patients and clinicians to navigate,with associated challenging decisions about who to treat,how,and *** such,the skill sets needed to manage the various aspects of the disease and guide patients appropriately outstrips the capabilities of one particular specialist,and the evolution of a multispeciality approach to the management of kidney cancer is now *** this Review,we summarise the current best multispeciality practice for the management of localised kidney cancer and the areas in need of further research and development.

关键词： kidney local approach

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Primary lymphomas of the genitourinary tract:A population-based study

引用

Asian Journal of Urology 2020年第4期7卷 332-339页

作者： Carlotta Palumbo Elio Mazzone Francesco A.Mistretta Sophie Knipper Zhe Tian Paul Perrotte Francesco Montorsi Shahrokh F.Shariat Fred Saad Claudio Simeone Alberto Briganti Alessandro Antonelli Pierre I.Karakiewicz Cancer Prognostics and Health Outcomes Unit University of Montreal Health CenterMontrealQuebecCanada Urology Unit ASST Spedali Civili of BresciaDepartment of Medical and Surgical SpecialtiesRadiological Science and Public HealthUniversity of BresciaBresciaItaly Division of Experimental Oncology Unit of UrologyUrological Research Institute(URI)IRCCS San Raffaele Scientific InstituteMilanItaly Vita-Salute San Raffaele University MilanItaly Department of Urology European Institute of OncologyMilanItaly Martini Klinik University Medical Center Hamburg-EppendorfHamburgGermany Division of Urology University of Montreal Hospital Center(CHUM)MontrealQuebecCanada Department of Urology Comprehensive Cancer CenterMedical University of ViennaViennaAustria Department of Urology Weill Cornell Medical CollegeNew YorkNYUSA Department of Urology University of Texas SouthwesternDallasTXUSA Department of Urology Second Faculty of MedicineCharles UniversityPragCzech Republic Institute for Urology and Reproductive Health I.M.Sechenov First Moscow State Medical UniversityMoscowRussia

Objective:We performed a population-based analysis focusing on primary extranodal lymphoma of either testis,kidney,bladder or prostate(PGUL).Methods:We identified all cases of localized testis,renal,bladder and prostate primary lymphomas(PL)versus primary testis,kidney,bladder and prostate cancers within the Surveillance,Epidemiology,and End Results database(1998e2015).Estimated annual proportion change methodology(EAPC),multivariable logistic regression models,cumulative incidence plots and multivariable competing risks regression models were ***:The rates of testis-PL,renal-PL,bladder-PL and prostate-PL were 3.04%,0.22%,0.18%and 0.01%,*** with PGUL were older and more frequently *** rates significantly decreased for renal-PL(EAPC:5.6%;pZ0.004)and prostate-PL(EAPC:3.6%;pZ0.03).In multivariable logistic regression models,older ager independently predicted testis-PL(odds ratio[OR]:16.4;p<0.001)and renal-PL(OR:3.5;p<0.001),while female gender independently predicted bladder-PL(OR:5.5;p<0.001).In surgically treated patients,cumulative incidence plots showed significantly higher 10-year cancer-specific mortality(CSM)rates for testis-PL,renal-PL and prostate-PL versus their primary genitourinary *** multivariable competing risks regression models,only testis-PL(hazard ratio[HR]:16.7;p<0.001)and renal-PL(HR:2.52;p<0.001)independently predicted higher CSM ***:PGUL rates are extremely low and on the decrease in kidney and prostate but stable in testis and *** to primary genitourinary tumors,PGUL are associated with worse CSM for testis-PL and renal-PL but not for bladder-PL and prostate-PL,even after adjustment for other-cause mortality.

关键词： Bladder lymphoma Genitourinary neoplasm Genitourinary Primary extranodal lymphoma Prostate lymphoma Renal lymphoma Testis lymphoma Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy:long-term results from a non-randomised,open-label,phase 1/2 trial and expanded access

引用

四川生理科学杂志 2021年第11期43卷 2002-2002页

作者： Francesca Fumagalli San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) IRCCS San Raffaele Scientific Institute Milan Italy Pediatric Immunohematology Unit and BMT Program IRCCS San Raffaele Scientific Institute Milan Italy Units of Neurology and Neurophysiology IRCCS San Raffaele Scientific Institute Milan Italy Department of Neurology ASST Papa Giovanni XXIII Bergamo Italy Neuroradiology Unit IRCCS San Raffaele Scientific Institute Milan Italy University Centre of Statistics in the Biomedical Sciences (CUSSB) Milan Italy Vita-Salute San Raffaele University Milan Italy

Background:Effective treatment for metachromatic leukodystrophy(MLD)remains a substantial unmet medical *** this study we investigated the safety and efficacy of atidarsagene autotemcel(arsa-cel)in patients with ***:This study is an integrated analysis of results from a prospective,non-randomised,phase 1/2 clinical study and expanded-access frameworks.29 paediatric patients with pre-symptomatic or early-symptomatic early-onset MLD with biochemical and molecular confirmation of diagnosis were treated with arsa-cel,a gene therapy containing an autologous haematopoietic stem and progenitor cell(HSPC)population transduced ex vivo with a lentiviral vector encoding human arylsulfatase A(ARSA)cDNA.

关键词： dystrophy diagnosis expanded

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

引用

World Journal of Gastrointestinal Oncology 2023年第11期15卷 1900-1912页

作者： Sirish Dharmapuri UmutÖzbek Hiren Jethra Tomi Jun Thomas U Marron Anwaar Saeed Yi-Hsiang Huang Mahvish Muzaffar Matthias Pinter Lorenz Balcar Claudia Fulgenzi Suneetha Amara Arndt Weinmann Nicola Personeni Bernhard Scheiner Tiziana Pressiani Musharraf Navaid Bertram Bengsch Sonal Paul Uqba Khan Dominik Bettinger Naoshi Nishida Yehia Ibrahim Mohamed Arndt Vogel Anuhya Gampa James Korolewicz Antonella Cammarota Ahmed Kaseb Peter R Galle Anjana Pillai Ying-Hong Wan Alessio Cortellini Masatoshi Kudo Antonio D’Alessio Lorenza Rimassa David James Pinato Celina Ang Tisch Cancer Institute Icahn School of Medicine at Mount SinaiNew YorkNY 10029United States Department of Population Health Science and Policy Icahn School of Medicine at Mount SinaiNew YorkNY 10029United States Department of Data Analytics Harrisburg Harrisburg University of Science and TechnologyHarrisburdPA 17101United States SEMA4 StamfordCT 06902United States Division of Medical Oncology Kansas University of Kansas Cancer CenterKansasMO 66160United States Division of Gastroenterology and Hepatology Taipei Veterans General HospitalTaipei 11217Taiwan Department of Internal Medicine Brody School of MedicineEast Carolina UniversityGreenvilleNC 27858United States Department of Internal Medicine III Division of Gastroenterology and HepatologyMedical University of ViennaVienna 1090Austria Department of Surgery and Cancer Imperial College LondonHammersmith Hospital LondonLondon W120HSUnited Kingdom Department of Hepatology Johannes Gutenberg-University Medical CentreNiedersachsen 30625Germany Medical Oncology Unit ASST GardaVia Lungomella ValsecchiBresciaManerbio 25025Italy Medical Oncology and Hematology Unit Humanitas Cancer CenterIRCCS Humanitas Research HospitalMilanRozzano 20089Italy Department of Medicine II Univ Med Ctr FreiburgHugstetter Str 55University Hospital FreiburgFreiburg D-79106Germany Department of Oncology Baltimore LifeBridge HealthBaltimoreMD 21215United States Division of Hematology and Oncology Weill Cornell Medical CollegeNY 10065United States Department of Gastroenterology and Hepatology Kindai University Faculty of MedicineOsaka 577-8502Japan Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer CenterHoustonTX 77030United States Department of Gastroenterology Hepatology and Endocrinology HannoverArndt VogelMedical School HannoverCarl-Neubergstr.Hannover 30659Germany Department of Hepatology Rush University Medical Group 1725 W Harrison St Ste 158ChicagoIL 60612United States Department of Biomedica

BACKGROUND A well-recognized class effect of immune checkpoint inhibitors(ICI)is immune-related adverse events(IrAEs)ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of *** are reported in300 was significantly associated with a lower incidence of grade≥2 IrAEs(OR=0.40;P=0.044).Similarly,a trend was observed between NLR>5 and lower incidence of grade≥2 IrAEs(OR=0.58;P=0.097).Multivariate analyses confirmed PLR>300 as an independent predictive marker of grade≥2 IrAEs(OR=0.26;P=0.011),in addition to treatment with programmed cell death ligand 1(PD-1)/cytotoxic T lymphocyte-associated protein-4(OR=2.57;P=0.037)and PD-1/tyrosine kinase inhibitor(OR=3.39;P=0.01)*** use was not associated with IrAE incidence(OR=1.02;P=0.954).Patients treated with steroids had a>2-fold higher incidence of gr

关键词： Neutrophil-lymphocyte ratio Platelet-lymphocyte ratio Inflammatory biomarkers Immunotherapy Immune toxicity

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

First-line pazopanib in patients with advanced non-clear cell renal carcinoma:An Italian case series

引用

World Journal of Clinical Oncology 2021年第11期12卷 1037-1046页

作者： Sebastiano Buti Melissa Bersanelli Francesco Massari Ugo De Giorgi Orazio Caffo Gaetano Aurilio Umberto Basso Giacomo Carteni Claudia Caserta Luca Galli Francesco Boccardo Giuseppe Procopio Gaetano Facchini Giuseppe Fornarini Alfredo Berruti Elena Fea Emanuele Naglieri Fausto Petrelli Roberto Iacovelli Camillo Porta Alessandra Mosca Medical Oncology Unit University Hospital of ParmaParma 43126Italy Medicine and Surgery Department University of ParmaParma 43126Italy Division of Oncology Policlinico Sant’Orsola-Malpighi HospitalBologna 40138Italy Department of Oncology IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(I.R.S.T.)Meldola 47014Italy Department of Medical Oncology Santa Chiara HospitalTrento 38122Italy Department of Medical Oncology Division of Urogenital and Head and Neck TumoursEuropean Institute of Oncology IRCCSMilan 20141Italy Medical Oncology Unit 3 Istituto Oncologico Veneto IOV IRCCSCastelfranco VenetoPadova 31033Italy Division of Oncology Azienda Ospedaliera di Rilievo Nazionale A.CardarelliNapoli 80131Italy Medical Oncology Unit Azienda Ospedaliera S.MariaTerni 05100Italy Oncology Unit 2 University Hospital of PisaPisa 56126Italy Academic Unit of Medical Oncology IRCCS San Martino Polyclinic HospitalGenova 16132Italy Medical Oncology Genitourinary Section Fondazione IRCCS Istituto Nazionale Dei TumoriMilan 20133Italy Departmental Unit of Clinical and Experimental Uro-Andrologic Oncology Istituto Nazionale Tumori IRCCS Fondazione G.PascaleNapoli 80131Italy Medical Oncology Unit Istituto di Ricovero e Cura a Carattere Scientifico(IRCCS)Ospedale Policlinico San MartinoGenova 16132Italy University of Brescia ASST-Spedali CiviliBresciaBrescia 25123Italy Medical Oncology Unit S Croce and Carle Teaching HospitalCuneo 12100Italy Division of Medical Oncology Istituto Tumori G Paolo IIIRCCSBari 70124Italy Medical Oncology Unit ASST Bergamo OvestTreviglioBergamo 24047Italy Medical Oncology Unit Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome 00161Italy Division of Oncology AOU Consorziale Policlinico di BariBari 70124Italy Department of Biomedical Sciences and Human Oncology University of Bari"A.Moro"Bari 70124Italy Multidisciplinary Outpatient Oncology Clinic Candiolo Cancer InstituteFPO-IRCCSCandioloTurin 10060Italy

BACKGROUND Non-clear cell(ncc)metastatic renal-cell carcinoma(RCC)has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell *** systemic combination therapies have emerged for metastatic RCC(mRCC),but the pivotal phase III trials excluded patients with nccRCC,which constitute about 30%of metastatic RCC *** To provide a piece of real-life evidence on the use of pazopanib in this patient *** The present study is a multicenter retrospective observational analysis aiming to assess the activity,efficacy,and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life *** Overall,48 patients were *** the median follow-up of 40.6 mo,the objective response rate was 27.1%,the disease control rate was 83.3%,and the median progression-free survival and overall survival were 12.3(95%confidence interval[CI]:3.6-20.9)and 27.7(95%CI:18.2-37.1)mo,*** 3 adverse events occurred in 20%of patients,and no grade 4 or 5 toxicities were *** Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.

关键词： Pazopanib Non-clear cell Kidney cancer Renal-cell carcinoma Variant histology Tyrosine kinase inhibitors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

前庭性偏头痛诊断标准(更新):Bárány协会及国际头痛协会共识文件

引用

神经损伤与功能重建 2022年第10期17卷 559-562页

作者：邢玥(译) 凌霞(译) 王钰茹(译) 荣良群(审校) 杨旭(审校) Thomas Lempert Jes Olesen Joseph Furman John Waterston Barry Seemungal John Carey Alexander Bisdorff Maurizio Versino Stefan Evers Amir Kheradmand David Newman-Toker 航天中心医院(北京大学航天临床医学院)神经内科徐州医科大学第二附属医院神经内科德国柏林Schlosspark-Klinik医院神经病学科丹麦哥本哈根大学头痛中心和神经病学系美国宾夕法尼亚州匹兹堡大学耳鼻喉科学系及神经病学系澳大利亚墨尔本阿尔弗雷德医院莫纳什大学神经科学系英国伦敦Charing Cross医院临床神经科学系美国马里兰州巴尔的摩约翰·霍普金斯大学医学院耳鼻喉头颈外科学系卢森堡阿尔泽特河畔埃施医学中心神经病学系意大利瓦雷泽Ospedale di Circolo asst Sette Laghi医院神经病学科和卒中单元意大利瓦雷泽英苏布里亚大学德国Coppenbrügge Krankenhaus Lindenbrunn医院神经病学科美国马里兰州巴尔的摩约翰·霍普金斯大学医学院神经病学系

本文介绍了由Bárány协会国际前庭疾病分类(International Classification of Vestibular Disorders,ICVD)委员会和国际头痛协会(International Headache Society,IHS)偏头痛分类小组共同制定的前庭性偏头痛(vestibular migraine,VM)的诊断标准。本文包含了部分文献更新,原2012版本的诊断标准仍然不变。诊断标准包括VM和很可能的VM两类。根据常规的IHS流程,VM作为一个新的疾病类型,将首先被纳入第三版国际头痛分类(International Classification of Headache Disorders,ICHD)的附录。随着研究证据的进一步增加,很可能的VM也有待被纳入到未来的ICHD版本中。VM的诊断包括:反复发作的前庭症状、偏头痛的病史、前庭症状与偏头痛症状存在时间关联,且排除其他可能导致前庭症状发生的相关病因。符合VM诊断的症状包括多种类型:如眩晕、头动诱发的头晕伴恶心等,但临床上,上述症状的严重程度须为中度或重度,急性发作的持续时间需在5 min~72 h。

关键词：偏头痛眩晕头晕前庭诊断标准 Bárány协会国际头痛协会

来源：

维普期刊数据库

同方期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

免疫疗法联合立体定向放疗治疗非小细胞肺癌脑转移:一项AIRO多中心回顾性研究

引用

中国肺癌杂志 2022年第4期25卷 I0007-I0022页

作者： Silvia SCOCCIANTI Emanuela OLMETTO Valentina PINZI Mattia Falchetto OSTI Rossella Di FRANCO Saverio CAINI Paola ANSELMO Paolo MATTEUCCI Davide FRANCESCHINI Cristina MANTOVANI Giancarlo BELTRAMO Francesco PASQUALETTI Alessio BRUNI Paolo TINI Emilia GIUDICE Patrizia CIAMMELLA Anna MERLOTTI Sara PEDRETTI Marianna TRIGNANI Marco KRENGLI NiccolòGIAJ-LEVRA Isacco DESIDERI Guido PECCHIOLI Paolo MUTO Ernesto MARANZANO Laura FARISELLI Pierina NAVARRIA Umberto RICARDI Vieri SCOTTI Lorenzo LIVI 王绿化(翻译/校对) Radiation Oncology Unit Ospedale Santa Maria AnnunziataDepartment of OncologyBagno a RipoliFlorenceItaly Radiation Oncology Unit Azienda Ospedaliero Universitaria CareggiDepartment of Experimental and Clinical Biomedical Sciences"Mario Serio"FlorenceItaly U.O Radioterapia Fondazione IRCCS Istituto Neurologico Carlo BestaDepartment of NeurosurgeryMilanItaly U.O.C Radioterapia A.O.U Sant'Andrea Facolta Medicina e Psicologia Universita SapienzaDepartment of MedicineSurgery and Translational MedicineRomeItaly Istituto Nazionale Tumori IRCCS Fondazione G.PascaleDepartment of RadiotherapyNaplesItaly Institute for Cancer Research Prevention and Clinical Network(ISPRO)Cancer Risk Factors and Life-Style Epidemiology UnitFlorenceItaly Radiotherapy Oncology Center S.Maria HospitalDepartment of OncologyTerniItaly Humanitas Research Hospital Radiotherapy and Radiosurgery DepartmentRozzanoItaly Radiotherapy Unit Department of OncologyTurinItaly Cyberknife Centro Diagnostico Italiano Department of RadiologyMilanItaly Radiation Oncology Azienda Ospedaliero Universitaria PisanaDepartment of Translational MedicinePisaItaly Radiotherapy Unit University Hospital of ModenaDepartment of Oncology and HematologyModenaItaly Radiotherapy Unit University of SienaDepartment of Radiotherapy and OncologySienaItaly UOC di Radioterapia Policlinico Universitario Tor VergataDepartment of Onco-HaematologyRomeItaly Radioterapia Oncologica"G.Prodi "AO-IRCCS Arcispedale S.Maria NuovaDepartment of Oncology and Advanced TechnologyReggio EmiliaItaly Radiation Oncology A.S.O.S.Croce e Carle Department of Radiation OncologyCuneoItaly U.O.Radioterapia Oncologica Department of Radiation OncologyASST Spedali Civili di Brescia e Universita degli studi di BresciaBresciaItaly U.O.C.Radioterapia Oncologica Ospedale Clinicizzato SS Annunziata-Universita Chieti G.D'AnnunzioDepartment of Radiation OncologyChietiItaly Radiation Oncology University Hospital Maggiore della CaritdDepartment of Translational Medicine

背景与目的通过意大利放射治疗和临床肿瘤学学会(Italian Association of Radiotherapy and Clinical Oncology, AIRO)的一项多中心回顾性研究,明确免疫疗法(immunotherapy, IT)和立体定向放疗(stereotactic radiotherapy,SRT)包括放射外科治疗(radiosurgery, RS)或大分割立体定向放疗(hypofractionated stereotactic radiotherapy, HFSRT)治疗非小细胞肺癌(non-small cell lung cancer, NSCLC)脑转移的疗效和毒性。方法对来自19个意大利中心接受SRT+IT的NSCLC伴脑转移患者进行分析,并与单独接受SRT的对照组患者进行比较。结果共纳入SRT+IT组100例和单独SRT组50例。接受SRT+IT的患者有更长的颅内局部无进展生存期(intracranial local progression-free survival, i LPFS)(经倾向性评分调整后,P=0.007)。在诊断为脑转移时接受IT合并有颅外进展的患者中(n=24),接受SRT后再进行IT与较好的总生存期(overall survival, OS)相关(P=0.037)。多因素分析显示组织学类型为非腺癌、卡氏体能状态(Karnofsky performance status,KPS)评分=70分以及接受HFSRT与显著减少的生存期相关(P值分别为0.019、0.017和0.007)。与SRT和IT治疗间隔>7天(n=10)相比,治疗间隔≤7天(n=90)与更长的OS相关(经倾向性评分调整后,P=0.008)。联合治疗耐受性良好。在放射性坏死方面,接受SRT+IT的患者与单独SRT的患者无显著差异。SRT和IT的治疗间隔对毒性发生率无影响。结论 SRT+IT是一种安全的联合治疗方法,与单独SRT相比,具有更长的i LPFS。

关键词：立体定向放疗回顾性研究脑转移倾向性评分临床肿瘤学免疫疗法放射治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

神经重症监护患者的液体治疗:ESICM专家共识及临床实践推荐

引用

国际脑血管病杂志 2019年第2期27卷 84-97页

作者： Mauro Oddo Daniele Poole Raimund Helbok Geert Meyfroidt Nino Stocchetti Pierre Bouzat Maurizio Cecconi Thomas Geeraerts Ignacio-Martin Loeches Herve Quintard Fabio Silvio Taccone Romergryko G. Geocadin Claude Hemphill Carole Ichai David Menon Jean-Francois Payen Anders Perner Martin Smith Jose Suarez Walter Videtta Elisa R. Zanier Giuseppe Citerio 何毅华(译) 常远(译) 王晓蔷(译) 潘速跃(译) Department of Medic al-Surgical Intensive Care Medicine Faculty of Biology and Medicine Centre Hospitalier Universitaire VauDOIs (CHUV) Lhiversity of Lausanne Rue du Bugnon 46 B4 08.623 1011 Lausanne Switzerland Department of Intensive Care Medicine St James's Lhiversity Hospital James's St Ushers P.O. Box 580 Dublin & Ireland Service de Reanimation Medic o-chirurgic ale Hopital Pasteur 2 UniversiteCote d'Azur CHU de Nice 06000 Nice France Unite CNRS 7275 Sophia-Antipolis France Department of Intensive Care Erasme Hospital University Libre de Bruxelles Brussels Belgium Neurosciences Critical Care Departments of Anesthesiology and Critical Care Medicine Neurology and Neurosurgery Johns Hopkins Lhiversity Baltimore MD USA Department of Neurology University of California San Francisco San Francisco CA LKA Service de Reanimation Polyvalente Hopital Pasteur 2 CHU de Nice 30 Voie Romaine CS 51069 06001 Nice Cedex 1 France Division of Anaesthesia University of Cambridge Addenbrooke's Ffospital Box 93 Hfills Road Cambridge Cambridgeshire CB2 2QQ UK Department of Intensive Care 4131 Copenhagen University Hospital- Rigshospitalet Copenhagen Denmark Department of Neuroanesthesia and Neurocritic al Care The National Ffospital for Neurosurgery and Neurology Lhiversity College London Hospitals London UK Anesthesia and Intensive Care Operative th it S. Martino Hospital Belluno Italy Hospital Nacional Professor Alejandro Posadas Buenos Aires Argentina Department of Neurosciences IRCCS-Istituto di Ricerche Farmacotogiche Mario Negri Milan Italy School of Medicine and Surgery University of Milan-Bicocca Milan Italy Neurointensive Care San Gerardo Hospital ASST-Monza 20900 Monza Italy 南方医科大学南方医院神经内科广州510515 Neurological Intensive Care Lhit Department of Neurology Medical University of Innsbruck Innsbruck Austria Department of Intensive Care Medicine University Hospitals Leuven Louvain Belgium Neuroscience Intensive Care Unit Department of Anesthesia and C

目的发布欧洲重症医学学会(European Society of Intensive Care Medicine, ESICM)关于神经重症监护患者液体治疗的专家共识和临床实践推荐意见。设计在2016年10月召开的ESICM LIVE 2016会议上召集了一个由22名国际专家组成的共识委员会... 详细信息

目的发布欧洲重症医学学会(European Society of Intensive Care Medicine, ESICM)关于神经重症监护患者液体治疗的专家共识和临床实践推荐意见。设计在2016年10月召开的ESICM LIVE 2016会议上召集了一个由22名国际专家组成的共识委员会,随后委员会成员通过电话会议和在线讨论制定本专家共识。方法回顾人群、干预、对比和结局(population, intervention,comparison, and outcomes, PICO)问题,根据需要进行更新并得到证据概要。本共识关注3个主要议题:(1)神经重症监护患者的液体复苏和维持;(2)高渗液体在颅内压控制中的应用;(3)蛛网膜下腔出血后迟发性脑缺血的液体管理。经过广泛的文献检索,应用推荐分级的评估、制订与评价(Gradingof Recommendations Assessment, Development and Evaluation, GRADE)系统原则评估证据质量(从高到极低),制定治疗推荐(强或弱),并在适用时发布最佳实践声明。基于文献和专家意见提供的综合证据,应用改良德尔菲方法(使用序贯方法以避免偏倚和误解)产生最终共识声明。结果最终共识包含总共32条声明,其中13条为强推荐,17条为弱推荐,另外2条声明未提供推荐意见。结论我们发布了一份关于神经重症监护患者液体治疗的共识声明和临床实践推荐。

关键词：循证医学指南液体治疗创伤性脑损伤蛛网膜下腔出血脑出血卒中甘露醇高渗神经重症监护

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Human genetic and immunological determinants of critical COVID-19 pneumonia

引用

四川生理科学杂志 2021年第11期43卷 1947-1947页

作者： Qian Zhang St Giles Laboratory of Human Genetics of Infectious Diseases Rockefeller Branch The Rockefeller University New York NY USA Laboratory of Human Genetics of Infectious Diseases Necker Branch INSERM U1163 Necker Hospital for Sick Children Paris France University of Paris Imagine Institute Paris France Howard Hughes Medical Institute Paris France The Rockefeller University & Howard Hughes Medical Institute New York NY USA Necker Hospital for Sick Children & INSERM Paris France Department of Pediatrics Necker Hospital for Sick Children Paris France Cemil Taşcıoglu City Hospital Istanbul Turkey Laboratory of Human Genetics of Infectious Diseases Necker Branch INSERM U1163 Necker Hospital for Sick Children Paris France Imagine Institute University of Paris Paris France Al Jalila Children’s Hospital Dubai United Arab Emirates San Raffaele Telethon Institute for Gene Therapy IRCCS Ospedale San Raffaele and Vita Salute San Raffaele University Milan Italy Hospices Civils de Lyon Lyon France Helix San Mateo CA USA Department of Intensive Care Medicine Critical Care Center CHU Lille Lille France Univ. Lille CNRS Inserm CHU Lille Institut Pasteur de Lille U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité deLille Lille France Shupyk National Medical Academy for Postgraduate Education Kiev Ukraine Department of Medical Microbiology University Medical Center Utrecht Utrecht The Netherlands Sidra Medicine Doha Qatar Primary Immunodeficiencies Group Department of Microbiology and Parasitology School of Medicine University of Antioquia Medellín Colombia School of Microbiology University of Antioquia Medellín Colombia IIBB-CSIC IDIBAPS Barcelona Spain Department of Immunology Second Faculty of Medicine Charles University University Hospital in Motol Prague Czech Republic Department of Immunology Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology Moscow Russia Pulmonology Department Cliniques Universitaire

SARS-CoV-2 infection is benign in most individuals but,in-10%of cases,it triggers hypoxemic COVID-19 pneumonia,which becomes critical in-3%of *** ensuing risk of death(-1%)doubles every five years from childhood onward and is-1.5 times greater in men than in *** are the molecular and cellular determinants of critical COVID-19 pneumonia?Inborn errors of type I IFNs,including autosomal TLR3 and X-linked TLR7 deficiencies,are found in-1-5%of patients with critical pneumonia under 60 years old.

关键词： pneumonia critical cases

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：